Biotech Values

[dewophile]

to be clear - I have very limited experience giving mifepristone..however I do have a lot of experience with hyperplasia, which is a condition that is very treatable, preventable with periodic induction of progestin withdrawals, so in the worst case scenario still shouldn't kill proellex in terms of risk-benefit when you think about patients who are hemorrhaging vaginally
but most of all, the data in hand, supported by reassuring biopsy data from similar agents as pointed out by rfj, leads me to think there won't be any marked risk for hyperplasia, and really that is the only risk overhang here given the profound efficacy